In-demand producer/DJ also talks to MTV News about upcoming projects with No Doubt, Snoop Dogg, more. By Zachary Swickey
Diplo performs in Madison, Wisconsin on Tuesday Photo: Evan Scott/MTV News
MADISON, Wisconsin It was just four years ago that Diplo put his production prowess on full display with M.I.A.'s mega-hit "Paper Planes." Since then, the DJ/producer has become a go-to producer for major acts like Usher, whose latest single, R&B jam "Climax," features work from the Philadelphia native.
On Tuesday, MTV News hit up the first stop on the campus-themed AXE One Night Only Tour in Wisconsin, and we caught up with the headlining DJ to talk about his upcoming projects.
"We got really luck on that one," he said of the track from Usher's upcoming album. "We just had great chemistry. I was super-nervous working with him the first two days. ... The way we did it, it was just a super-open format. He was down to do whatever we were excited about.
"I love Usher," Diplo gushed. "I'm an Usher fan. I love him for records like 'Confessions Pt. II' and 'Burn,' those are some of the first R&B records from my generation that are still lasting forever. And we did some uptempo stuff too. I don't know what'll make the album, but I think there are definitely three songs that'll make it."
Diplo is currently involved with a number of projects and luckily he was willing to dish. After working last summer with No Doubt on their upcoming record, the producer revealed he had good news to share.
"We just finished. I was actually in Jamaica last month and I went in and did some extra stuff on that record," he told us. "I'm super-excited. It's probably going to be a single for their album. They've been [tweeting] about the song, so they're excited about it. I think it's going to be a 'No Doubt featuring Major Lazer' record, because we were producers, and there's another artist on it, too, that we recorded in Jamaica.
"But you'll have to wait," Diplo warned, "I don't know how far off that record is, but every song I've heard is a bona-fide hit. '
The superstar DJ also recently took to his Facebook page and casually mentioned that he's already started production on 18 tracks for a record with Snoop Dogg.
"Snoop Dogg is an icon, man; he's bigger than the music," Diplo said. "What we're doing is a reggae record. It's like Snoop Dogg and Major Lazer together. It's all reggae and he's singing and he's doing a f---ing awesome job and I never knew it, but he had his heart in every song. ... We're going to get back into the production of it next month, and I'm really proud of that record. It's the first record I've ever executive-produced and his crew is amazing.
The deal terms were undisclosed, however both Hayden and Marvin declined to buy the publically traded company WebDigs, Inc (WBDG) in order to keep their company privately owned. Hayden and Marvin formed an investment arm of Renters Warehouse known as Fiontrai II in early 2012 and have been seeking to acquire local property management and real estate companies. ?Fiontrai??means ?Entrepreneur?in Irish. This isn?t Hayden or Marvin?s first go around, both having ownership in 8 other local companies, despite Hayden (26) and Marvin?s (28) young ages.
Brenton Hayden and Ryan Marvin purchased assets of the innovative and once publically traded WebDigs (WBDG). Hayden and Marvin, both Minnesota natives and young entrepreneurs who formed Renters Warehouse in 2007, and since have developed it to become the largest residential property management company in Minnesota, and the fastest growing privately held company in Minnesota according to Inc. magazines Inc. 500/5000 list.
You?ve ?u?t bought a new car but d?f?n?tely feel th?t th? factory-made rims ?nd wheels hav? to go. After all, the? are oh-so-boring and plain, n?t t? mention ?v?ry ?ther driver w?th the sam? make and model w?ll have the ?ame set ?f wheels. So ??u h?ve made th? decision to change the rims to ?ometh?ng which suits y?ur personality. Well, y?u ?r? d?finitel? open f?r choice b??ause ther? ar? m?n? diff?rent custom wheels th?t y?u c?n purchase. For starters k??? in mind th?t the price ?f ???h set of wheels will vary depending on th? manufacturer and ?r auto shop you buy th?m from. A general rule ?f thumb i? th?t ?f ??u pay le?? that i? wh?t y?u w?ll ultimately get. We ?r? n?t advocating buying expensive custom wheels r?ther you ne?d t? be careful ?f wh?t you buy be??u?? ?ou w?nt to watch out for quality. It w?uld b? ap?r??r?ate ?f at th?? point ?n time ?ou start thinking ?f ??ur budget f?r ?our custom wheels. How much are ?ou will?ng t? pay for them?
Additionally, d?d ?ou know th?t b? changing y?ur cars? wheels and rims, ?ou ?ould unintentionally ??u?e ??ur car manufacturer?s warranty t? b?come null ?nd void? This ?? th? reason wh? ?ou n??d t? select ?n auto shop whi?h ??n give ?ou the be?t advice ?nd information if ??u w?nt to purchase custom wheels. You d? n?t w?nt to accidentally purchase wheels that l??k gorgeous but d?n?t fit the specifications ?nd end up w?th m?re troubles ?n the end. First off, h?v? a l?ok at your vehicle. Depending ?n how heavy ?t is, y?u n??d t? select suitable wheels that ?an bear ?t? weight. A wheel wh?ch ?? t?? big might c?us? problems to y?ur car?s brake system wh?le one which i? t?o small ??uld v?ry w?ll make ?t difficult for y?u t? turn. Typical custom wheels th?t ??u ?an choose w?uld be made ?f alloy or steel. Light alloy wheels will reduce the ov?r?ll weight ?f your vehicle ?nd that ?n turn means ?our vehicle i? now consuming l?s? petrol.
These type ?f wheels w?ll also be a good choice for you if y?u frequently encounter stop-go traffic while on the roads. You will n?t face ?ver heating ?f u??ng light alloy wheels b???u?e the? ?llow air to flow ?nto ??ur brakes. On th? other hand, if ?ou plan to u?e y?ur vehicle f?r heavy lifting ?r if ?ou will frequently us? back roads t? transport items, ?ou should opt for custom wheels made ?f steel b?caus? th?? ar? sturdy. Before a?tuall? purchasing y?ur new set ?f custom wheels, th?r? ?re s?me technical details ?f your car wh??h ?ou should b? aware of. What ?? th? maximum load rating ?f your car? Your n?w wheels ?h?uld b? compatible with that b???u?e ?f it isn?t, problems w?ll occur in th? future. You m?ght n?t th?nk much of it but ?a?h part of the car plays ?t? own role. A tiny or slight variation fr?m that w?ll affect the performance ?f y?ur car.
As such, when buying wheels, make ?ure th?t th?y have th? ??me bolt pattern ?? the ?nes you alre?d? h?v? ?n the vehicle. It w?uld be v?ry strange if ?ou eventually bought custom wheels th?t did n?t fit b?c?use the bolts ar? n?t ?n the ??m? place. Now th?t ?ou h?ve ? general idea of y?ur budget ?nd th? technical aspect of purchasing custom wheels, y?u ??n relax ? littl? ?nd think ab?ut th? style ?f wheels and rims that y?u w?nt ?n y?ur car. After all, that is th? reason why y?u decided t? g?t ? new set of wheels in the f?r?t place. You w?nt ?om?thing th?t mirrors ??ur personality ?nd give? y?ur car a l?ttl? bit of th?t extra jazz. If you ?re ?onsid?ring showing y?ur classic car then be ?ure ??u kn?w th? judges rules on custom rims.
This entry was posted on March 28, 2012, 3:49 pm and is filed under Automotive, Classic Cars, New Car Show. You can follow any responses to this entry through RSS 2.0.
Both comments and pings are currently closed.
Canon and Nikon both have brand new professional DLSR cameras fighting for the wallets of photographers and videographers the world over. We recently reviewed the Canon 5D Mark III, and are whipping up a review of the Nikon D800. In the meantime, we put together a comparison of the video capabilities of these two foes. More »
Windows XP is a few years old now, to so many different cleaning companies register for them. This level of choice is great, but it also means that you can be sure that you have the best registry cleaner to fix your computer the best way possible.
need
While there are so many registry cleaners, they were all designed to do the same job. They were all created for part of your system as a ?registration? to eliminate. This is the central database for Windows, the settings and options for your computer so that XP on all of your e-mail your current desktop.
remember
This database is the heart and soul of Windows XP and is used continuously while you are on your computer. Each time you open your PC 100 is the registry files and processed by your system to help ?remember? many parameters and options.
This is fine, but the problem is that XP is often confused and ends up saving many of these files in the wrong direction, they are corrupt and do damage. This makes all files (inverted like a book with all the chapters) and read one another extremely difficult. Clean the correct, you should use a registry cleaner, but you must also ensure you have the best cleaner for XP.
There are many registry cleaners, parts of the registry XP but only a few that work best. We found the best XP registry cleaners are those who find and fix most problems on your computer so it is easy to open any file and registry, it will speed up your PC and can run much smoother. And the cleaners that do this are those that are constantly updated to the latest problems in the registry that XP should use to throw around.
We have the best XP registry cleaner Wh per day to those found growing in popularity due to its unique and powerful features, including an advanced UEL are simple, but effective, how RegAce. This registry cleaner is very popular, with 1,000 ?s of downloads per day, with features such as advanced registry scanner (which is harder than any other cleaner) and a backup function complete (which gives the way back up your entire computer before cleaning the registry).
HTML Ready Article. Click on the "Copy" button to copy into your clipboard.
By: Ellie Lewis
The idea of creating a will and planning for the end of your life is never a fun experience. Even if you are not bothered by the idea of your own life ending, your family may have a hard time coping with the planning and it will be an altogether unpleasant experience. While you may not feel like planning for your death is a walk in the park, it is a necessary evil that will put your mind at ease and help your family cope with a difficult time period. A lawyer will be able to help you with the planning. If you have worked with an attorney concerning expense reduction or contract negotiation issues, that same attorney can probably help you with creating a will. Creating a will is fairly easy and some people do it without even using a lawyer, but it is probably better to have a professional look over your final documents just to be sure things are in order and your family will not face any problems. It is important for your intentions to be clear.
A will helps you ensure your family is protected. If you have any assets whatsoever, they are at risk when you die. Most people assume their assets will automatically pass to their spouse or their children without much interference. Most of the time, this is the case. But there are situations in which other family members get greedy or scam artists use the death of a loved one to take advantage of a family. You can ensure this does not happen to your family once you are gone by making your intentions for your assets clear in your will. Having a lawyer to back up your wishes will protect your family from any risk they may face after your death.
Wills prevent family members from arguing about things once you are gone. While you may love your family dearly and assume they will all be exactly who they are at this very moment, the truth is, people change. They may find themselves falling on hard financial times or they choose to marry someone who is not as scrupulous as you are. To avoid problems with your relatives, outline your intentions in your will. This legally binding document will prevent arguments and fighting once you are gone. While there is no telling how your family will cope with your death emotionally, at least you can remove financial issues from the equation.
While your main concern may be how your family is going to respond to your death, it is important to realize the government is going to want a piece of your pie once you are gone. The laws are constantly changing for inheritance issues, but if there is any way for the court system to prove something does not legally belong to your relatives, they will confiscate it. Protect your family from the intrusive efforts of the government following your death.
Finally, create a living will as part of your end of life planning strategy. Living wills make clear and legal your desire to have or not have life support. Creating a living will saves your loved ones the painful task of deciding whether or not to remove life support.
Author Resource:->??For more information on how to reduce expenses for your company go tohttp://www.cmpg.com/ .
Novel drug in pill form safer than standard approach to treat blocked lung blood vesselsPublic release date: 26-Mar-2012 [ | E-mail | Share ]
Contact: Beth Casteel bcasteel@acc.org 240-328-4549 American College of Cardiology
Simpler regimen should facilitate initial management on outpatient basis
CHICAGO -- A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism a blockage of lung blood vessels usually caused by a clot and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.
Pulmonary embolism (PE) and deep vein thrombosis (DVT), a blot clot generally occurring in the legs, constitute the two categories of a condition called venous thromboembolism (VTE). VTE is the third most common cardiovascular disease, and PE is the third most common cause of hospital-related death. EINSTEIN-PE is one of a series of large international phase III clinical trials of the anti-coagulant rivaroxaban to treat VTE or prevent a recurrence in patients with acute PE or DVT. The Food and Drug Administration has approved rivaroxaban as the only oral anti-coagulant for prevention of VTE in patients who have knee or hip replacement, procedures that carry clotting risks.
The trial compared rivaroxaban with standard therapy injection of the anti-coagulant enoxaparin, followed by a vitamin K antagonist (VKA; either warfarin or acenocoumarol) chosen by each participating site to demonstrate that the oral drug as a single agent is equivalent to the complicated two-drug standard therapy. In the standard regimen, enoxaparin must be given as an injection, and the VKA must be monitored with blood tests to make sure the dose is adequate and safe, because common drugs such as antibiotics, alcohol and some foods interact with VKAs. The monitoring measure is INR, an expression of the time it takes blood to clot: the higher the INR number, the higher the risk of bleeding.
"If you give standard treatment in the right way, it's a perfectly effective drug with almost 90 percent reduction in recurrent thrombosis, but it has to be well controlled," said Harry R. Buller, MD, PhD, professor of vascular medicine at the Academic Medical Center, Amsterdam, The Netherlands, who chairs the program for the three EINSTEIN studies. "The reason people look for alternatives is that it's a nightmare to give. Rivaroxaban makes things easier for everybody patients and physicians. Our major aim was to show that it's at least as good as standard care."
The study, conducted at 263 sites in 38 countries, randomly assigned 2,419 patients to the rivaroxaban arm and 2,414 to standard treatment. All enrolled patients had a primary diagnosis of PE, and 25 percent in both groups also had DVT. Patients were treated for three, six or 12 months (average, seven) as deemed appropriate by each clinician before randomization. The rivaroxaban group received 15 mg twice a day for three weeks followed by 20 mg once a day. In the standard-therapy arm, the regimen was enoxaparin at 1.0 mg per kg of body weight twice daily, continued at least five days and stopped when the INR was 2.0 or more for two consecutive days, plus a VKA started within 48 hours after randomization with dose adjustment to maintain an INR of 2.0 to 3.0.
Rivaroxaban's efficacy was highly significant for non-inferiority with 2.1 percent recurrences (50 events) vs. 1.8 percent (44 events) in the standard-therapy arm. On safety measures of bleeding, rivaroxaban did much better: principal safety measure of major or clinically relevant bleeding, 10.3 percent vs. 11.4 percent for standard treatment; for major bleeding alone, 1.1 percent vs. 2.2 percent for standard therapy. Rates for primary endpoints were similar in both study arms regardless of patient characteristics.
"Physicians want to know about major bleeding, the most important safety outcome, and rivaroxaban was highly significantly superior. This was our most astonishing finding," Dr. Buller said. "Rivaroxaban is just as good as standard treatment for PE these data are pretty convincing and this is an oral-only approach, which makes it very simple. The subcutaneous injections can be hazardous as well."
Researchers also will be doing a subgroup analysis of the 8,200 patients in the EINSTEIN-PE and EINSTEIN-DVT trials to see if they can identify a risk profile for patients who are likely to have bleeding problems on standard treatment or the new drug.
###
The trial was sponsored by Bayer HealthCare and Janssen Pharmaceuticals. Dr. Buller is reimbursed for patients who participate in the study, travel costs and administrative time, and those funds go to the hospital.
This study will be simultaneously published in the New England Journal of Medicine online at the time of presentation and will appear in the April 2012 print edition.
Dr. Buller will be available to the media on Monday, March 26, at 9:45 a.m. CDT in Media Room #1, McCormick Place North Level 1, Hall C1.
Dr. Buller will present the study "Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism: the EINSTEIN PE Study" on Monday, March 26, at 8 a.m. CDT during the Joint ACC/NEJM Late-Breaking Clinical Trials in the Main Tent of McCormick Place North.
About the American College of Cardiology
The American College of Cardiology (www.cardiosource.org) is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College transforms cardiovascular care and improves heart health as it supports and advocates for quality improvement, patient-centered care, payment innovation and professionalism. The ACC bestows credentials upon cardiovascular specialists who meet its stringent qualifications and leads the formulation of health policy, standards and guidelines. It provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Novel drug in pill form safer than standard approach to treat blocked lung blood vesselsPublic release date: 26-Mar-2012 [ | E-mail | Share ]
Contact: Beth Casteel bcasteel@acc.org 240-328-4549 American College of Cardiology
Simpler regimen should facilitate initial management on outpatient basis
CHICAGO -- A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism a blockage of lung blood vessels usually caused by a clot and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.
Pulmonary embolism (PE) and deep vein thrombosis (DVT), a blot clot generally occurring in the legs, constitute the two categories of a condition called venous thromboembolism (VTE). VTE is the third most common cardiovascular disease, and PE is the third most common cause of hospital-related death. EINSTEIN-PE is one of a series of large international phase III clinical trials of the anti-coagulant rivaroxaban to treat VTE or prevent a recurrence in patients with acute PE or DVT. The Food and Drug Administration has approved rivaroxaban as the only oral anti-coagulant for prevention of VTE in patients who have knee or hip replacement, procedures that carry clotting risks.
The trial compared rivaroxaban with standard therapy injection of the anti-coagulant enoxaparin, followed by a vitamin K antagonist (VKA; either warfarin or acenocoumarol) chosen by each participating site to demonstrate that the oral drug as a single agent is equivalent to the complicated two-drug standard therapy. In the standard regimen, enoxaparin must be given as an injection, and the VKA must be monitored with blood tests to make sure the dose is adequate and safe, because common drugs such as antibiotics, alcohol and some foods interact with VKAs. The monitoring measure is INR, an expression of the time it takes blood to clot: the higher the INR number, the higher the risk of bleeding.
"If you give standard treatment in the right way, it's a perfectly effective drug with almost 90 percent reduction in recurrent thrombosis, but it has to be well controlled," said Harry R. Buller, MD, PhD, professor of vascular medicine at the Academic Medical Center, Amsterdam, The Netherlands, who chairs the program for the three EINSTEIN studies. "The reason people look for alternatives is that it's a nightmare to give. Rivaroxaban makes things easier for everybody patients and physicians. Our major aim was to show that it's at least as good as standard care."
The study, conducted at 263 sites in 38 countries, randomly assigned 2,419 patients to the rivaroxaban arm and 2,414 to standard treatment. All enrolled patients had a primary diagnosis of PE, and 25 percent in both groups also had DVT. Patients were treated for three, six or 12 months (average, seven) as deemed appropriate by each clinician before randomization. The rivaroxaban group received 15 mg twice a day for three weeks followed by 20 mg once a day. In the standard-therapy arm, the regimen was enoxaparin at 1.0 mg per kg of body weight twice daily, continued at least five days and stopped when the INR was 2.0 or more for two consecutive days, plus a VKA started within 48 hours after randomization with dose adjustment to maintain an INR of 2.0 to 3.0.
Rivaroxaban's efficacy was highly significant for non-inferiority with 2.1 percent recurrences (50 events) vs. 1.8 percent (44 events) in the standard-therapy arm. On safety measures of bleeding, rivaroxaban did much better: principal safety measure of major or clinically relevant bleeding, 10.3 percent vs. 11.4 percent for standard treatment; for major bleeding alone, 1.1 percent vs. 2.2 percent for standard therapy. Rates for primary endpoints were similar in both study arms regardless of patient characteristics.
"Physicians want to know about major bleeding, the most important safety outcome, and rivaroxaban was highly significantly superior. This was our most astonishing finding," Dr. Buller said. "Rivaroxaban is just as good as standard treatment for PE these data are pretty convincing and this is an oral-only approach, which makes it very simple. The subcutaneous injections can be hazardous as well."
Researchers also will be doing a subgroup analysis of the 8,200 patients in the EINSTEIN-PE and EINSTEIN-DVT trials to see if they can identify a risk profile for patients who are likely to have bleeding problems on standard treatment or the new drug.
###
The trial was sponsored by Bayer HealthCare and Janssen Pharmaceuticals. Dr. Buller is reimbursed for patients who participate in the study, travel costs and administrative time, and those funds go to the hospital.
This study will be simultaneously published in the New England Journal of Medicine online at the time of presentation and will appear in the April 2012 print edition.
Dr. Buller will be available to the media on Monday, March 26, at 9:45 a.m. CDT in Media Room #1, McCormick Place North Level 1, Hall C1.
Dr. Buller will present the study "Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism: the EINSTEIN PE Study" on Monday, March 26, at 8 a.m. CDT during the Joint ACC/NEJM Late-Breaking Clinical Trials in the Main Tent of McCormick Place North.
About the American College of Cardiology
The American College of Cardiology (www.cardiosource.org) is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College transforms cardiovascular care and improves heart health as it supports and advocates for quality improvement, patient-centered care, payment innovation and professionalism. The ACC bestows credentials upon cardiovascular specialists who meet its stringent qualifications and leads the formulation of health policy, standards and guidelines. It provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sIIXApbRRPBPdTkns2ssKyBhARhEOj-53hYjJi14rfHu16pCHxv1tptgnyAenT4y1DtNMYQt1-JACMhIpsfuMFgli1sv4MI6bRdtDugpA=s0-d){kind=small}
Public release date: 26-Mar-2012
Share ]